About Phospholipid phosphatase-related protein type 5
Phospholipid phosphatase-related protein type 5 (PLPPR5) is a protein
from Homo sapiens identified by UniProt accession
Q32ZL2, 321 residues long.
MolForge cross-references it against 0 known binders and
36 disease associations.
Target properties
| Protein name | Phospholipid phosphatase-related protein type 5 |
|---|
| UniProt accession | Q32ZL2 |
|---|
| Gene | PLPPR5 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 321 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (36)
Diseases linked to this target (Open Targets).
- smoking status measurement · score 0.34
- pathological myopia · score 0.30
- smoking behaviour measurement · score 0.28
- smoking behavior · score 0.27
- neurofibrillary tangles measurement · score 0.25
- ovarian cancer · score 0.23
- health study participation · score 0.22
- psychotic symptoms · score 0.10
- breast adenocarcinoma · score 0.10
- prostate adenocarcinoma · score 0.10
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q32ZL2-F1 | alphafold | PREDICTED | 82.25 | — |
Amino-acid sequence (321 residues)
MPLLPAALTS SMLYFQMVIM AGTVMLAYYF EYTDTFTVNV QGFFCHDSAY RKPYPGPEDS SAVPPVLLYS LAAGVPVLVI IVGETAVFCL QLATRDFENQ EKTILTGDCC YINPLVRRTV RFLGIYTFGL FATDIFVNAG QVVTGNLAPH FLALCKPNYT ALGCQQYTQF ISGEEACTGN PDLIMRARKT FPSKEAALSV YAAMYLTMYI TNTIKAKGTR LAKPVLCLGL MCLAFLTGLN RVAEYRNHWS DVIAGFLVGI SIAVFLVVCV VNNFKGRQAE NEHIHMDNLA QMPMISIPRV ESPLEKVTSV QNHITAFAEV T
Explore Phospholipid phosphatase-related protein type 5 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets